^<90>Y Ibritumomab tiuxetan (Y2B8, Zevalin^( !R)) radioimmunotherapy is highly effective for patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma pretreated with Rituximab-containing chemotherapy (R-Chemo) : Japanese Multicenter Phase II Study

• OGURA M

収録刊行物

• Blood

  Blood 2006

詳細情報

• CRID: 1571135650574814464
• NII論文ID: 10021279954
• データソース種別:
  • CiNii Articles